[17]COHEN S N, CHANG A C Y, BOYER H W, et al.Construction of biologically functional bacterial plasmids in vitro[J].Proceedings of the National Academy of Sciences of the United States of America，1973，70（11）：3240-3244.
[18]HOGAN S, et al.Studies on the antiobesity activity of tetrahydrolipstatin, a potent and selective inhibitor of pancreatic lipase[J].International Journal of Obesity，1987，11（Suppl 3）：35-42.
[19]WEINTRAUB M.Long-term weight control study：conclusions[J].Clinical Pharmacology&Therapeutics，1992，51（5）：642-646.
[20]BRAY G A.Amphetamine：thejanus of treatment for obesity[J].Obesity Research，1994，2（3）：282-285.
[21]CAMPFIELD L A, SMITH F J, GUISEZ Y, et al.Recombinant mouse OB protein：evidence for a peripheral signal linking adiposity and central neural networks[J].Science，1995，269（5223）：546-549.
[22]HALAAS J L, et al.Weight-reducing effects of the plasma protein encoded by the obese gene[J].Science，1995，269（5223）：543-546.
[23]PELLEYMOUNTER M A, et al.Effects of the obese gene product on body weight regulation in ob/ob mice[J].Science，1995，269（5223）：540-543.
[24]STEPHENS T W, et al.The role of neuropeptide Y in the antiobesity action of the obese gene product[J].Nature，1995，377（6549）：530-532.
[25]MONTAGUE C T, e t a l.Congenital leptin deficiency is associated with severe early-onset obesity in humans[J].Nature，1997，387（6636）：903-908.
[26]FAROOQI I S, et al.Beneficial effects of leptin on obesity, T cellhyporesponsiveness, and neuroend ocrine/metabolic dysfunction of human congenitalleptin deficiency[J].The Journal of Clinical Investigation，2002，110（8）：1093-1103.
[27]ORAL E A, et al.Leptin-replacement therapy for lipodystrophy[J].New England Journal of Medicine，2002，346（8）：570-578.
[28]VAN MARKEN LICHTENBELT W D, et al.Cold-activated brown adipose tissue in healthy men[J].New England Journal of Medicine，2009，360（15）：1500-1508.
[29]HILL J O, WYATT H R, PETERS J C.Energy balance and obesity[J].Circulation，2012，126（1）：126-132.
[30]COHEN S N.DNA cloning：a personal view after 40 years[J].Proceedings of the National Academy of Sciences，2013，110（39）：15521-15529.
[31]OGDEN C L, CARROLL M D, KIT B K, et al.Prevalence of childhood and adult obesity in the united states，2011-2012[J].JAMA，2014，311（8）：806-814.
[32]BURKE L K, HEISLER L K.5-hydroxytryptamine medications for the treatment of obesity[J].Journal of Neuroendocrinology，2015，27（6）：389-398.
[33]CYPESS AARON M, et al.Activation of human brown adiposetissue by aβ3-adrenergic receptor agonist[J].Cell Metabolism，2015，21（1）：33-38.
[34]KAHAN S, ZVENYACH T.Obesity as a disease：current policies and implications for the future[J].Current Obesity Reports，2016，5（2）：291-297.
